**Background**
Progestins are synthetic versions of progesterone used extensively in oral contraception and hormone replacement therapy. These compounds play a critical role in regulating the menstrual cycle and managing various endocrine disorders. A key challenge in progestin development is balancing progestogenic activity with other steroid receptor interactions, such as androgenic or mineralocorticoid effects, to minimize side effects like edema or acne. Understanding the interaction between these compounds and the progesterone receptor (PR) and androgen receptor (AR) is essential for developing safer therapeutic options. In this context, we will introduce a fourth-generation progestin – Drospirenone.
**Definition**
Drospirenone (Dihydrospirorenone) is an orally active fourth-generation progestin that interacts with both the progesterone receptor (PR) and the androgen receptor (AR). According to the Drospirenone description, it is characterized by its antiandrogenic and antimineralocorticoid properties.
**In Vitro and In Vivo Studies**
The Drospirenone biological activity has been extensively studied across various cell lines and animal models. In vitro studies demonstrated that Drospirenone (10-150 µM, 24-48 h) exhibits cytotoxicity in PLHC-1 cells, with EC50 values ranging from 105 to 119 μM after 24 h exposure and 51 to 58 μM after 48 h exposure. Furthermore, treatment with Drospirenone (10-200 µM, 15-120 min) was found to increase ROS production in PLHC-1 cells. In human immortalized endometrial endothelial cells (HEEC), Drospirenone (0.01-10 µM, 24 h) significantly decreased the secretion of both plasminogen activator inhibitor-1 (PAI-1) and tissue plasminogen activator (tPA) via the AR. Additionally, when supplemented with mice liver S9 fraction, Drospirenone (1-100 µM, 72 h) caused DNA damage in MCF-7 cells.
Regarding Drospirenone In Vivo data, administration to adult female mice via oral gavage (10-100 mg/kg for five days) resulted in DNA damage in bone marrow cells. It was also observed that the genotoxicity of the compound was enhanced when combined with ethinylestradiol. For researchers seeking specific Drospirenone technical information, these results highlight the compound’s complex interaction with cellular DNA and the plasminogen activator system. In conclusion, Drospirenone is a potent fourth-generation progestin with significant antiandrogenic activity and potential genotoxic effects in specific biological contexts.
Keywords
Drospirenone, 67392-87-4, Dihydrospirorenone, Progesterone Receptor, Androgen Receptor, NR3C3, PLHC-1 cells, human immortalized endometrial endothelial cells, MCF-7 cell, Progestin, Inhibitor, inhibitor, inhibit
References
[1] Fuhrmann, U., et al., The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contraception, 1996. 54(4): p. 243-51.
[2] Muhn, P., et al., Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Pharmacological characterization in animal models. Contraception, 1995. 51(2): p. 99-110.
[3] Warming, L., et al., Safety and efficacy of drospirenone used in a continuous combination with 17beta-estradiol for prevention of postmenopausal osteoporosis. Climacteric, 2004. 7(1): p. 103-11.
[4] Marqueño A, et al. Drospirenone induces the accumulation of triacylglycerides in the fish hepatoma cell line, PLHC-1 [J]. Science of The Total Environment, 2019, 692: 653-659.
[5] Sabouni R, et al. Drospirenone effects on the plasminogen activator system in immortalized human endometrial endothelial cells [J]. Reproductive sciences, 2021, 28: 1974-1980.
[6] Mir A H, et al. Genotoxic effects of drospirenone and ethinylestradiol in human breast cells (in vitro) and bone marrow cells of female mice (in vivo) [J]. Drug and Chemical Toxicology, 2022, 45(4): 1493-1499.
[7] Motivala A, et al. Drospirenone for oral contraception and hormone replacement therapy: are its cardiovascular risks and benefits the same as other progestogens? [J]. Drugs, 2007, 67: 647-655.